Sobi to acquire Arthrosi Therapeutics, strengthening pipeline for the potential treatment of gout

Sobi has agreed to acquire private biotech Arthrosi for USD 950m upfront plus up to USD 550m in clinical, regulatory and sales milestones, adding pozdeutinurad (AR882) — a once-daily URAT1 inhibitor now fully enrolled in two global Phase 3 REDUCE studies with pivotal readouts expected in 2026 — to strengthen its gout franchise; the deal is expected to close in H1 2026, will be funded mainly via debt including a new facility from Handelsbanken and Danske Bank, and is forecast by management to be highly accretive to mid- to long-term growth and margins and to materially accelerate Sobi’s growth into the mid-2030s. Pozdeutinurad, which showed sustained sUA reduction, tophi dissolution and a favorable safety profile in Phase 2, targets patients inadequately controlled on first-line urate‑lowering therapy and could be a differentiated, potentially best‑in‑class option if Phase 3 and regulatory outcomes are favorable; Greater China rights are held by ApicHope, and the usual clinical and regulatory execution risks remain ahead of commercialization.

Analysis

Sobi has agreed to acquire private Arthrosi for USD 950 million upfront plus up to USD 550 million in development, regulatory and sales milestones, with the transaction expected to close in H1 2026 and financed mainly through existing credit facilities and a new facility arranged with Handelsbanken and Danske Bank. Management characterizes the deal as highly accretive to Sobi’s mid- to long-term growth and margin trajectory and forecasts that pozdeutinurad could materially accelerate group growth into the mid-2030s.

Pozdeutinurad (AR882) is a once-daily oral URAT1 inhibitor that completed Phase 2 showing sustained serum uric acid reduction, tophi dissolution and a well-tolerated safety profile; two global 12‑month Phase 3 trials (REDUCE 1 and 2) are fully recruited with pivotal readouts expected in 2026. The asset targets patients inadequately controlled on first-line urate‑lowering therapy and is positioned as a potential best‑in‑class differentiated therapy, although Greater China rights are retained by ApicHope.

Strategically, the acquisition expands Sobi’s gout franchise and addresses an expressed unmet need, supporting management’s commercialization argument given Sobi’s global footprint; Barclays and McDermott are advising on the deal.

Key near‑term risks include clinical and regulatory outcomes from the 2026 Phase 3 readouts, execution and integration risk as Arthrosi is folded into Sobi, and the financial impact of debt-funded consideration on leverage and cash flow until anticipated accretion materializes.

Key Decisions for Investors

• Monitor the REDUCE 1 and REDUCE 2 Phase 3 readouts in 2026 and be prepared to add exposure on clear positive pivotal efficacy/safety data and favorable regulatory signals,
• Review Sobi's upcoming earnings guidance and pro forma leverage metrics carefully given the USD 950m upfront financed mainly by debt; consider hedging or reducing exposure if leverage or near‑term cash burn concerns emerge,
• Track commercial rights segmentation (Greater China held by ApicHope) and milestone structure to model upside and timing of potential revenue recognition,
• Listen to the December 15 conference call and review the slides for management’s detailed integration plan, funding draw schedule and updated commercialization assumptions